Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013:2013:609395.
doi: 10.1155/2013/609395. Epub 2013 Dec 23.

Th17-associated cytokines as a therapeutic target for steroid-insensitive asthma

Affiliations
Review

Th17-associated cytokines as a therapeutic target for steroid-insensitive asthma

Yuko Morishima et al. Clin Dev Immunol. 2013.

Abstract

Steroid-insensitive asthma is an infrequent but problematic airway disease that presents with persistent symptoms, airflow limitation, or recurrent exacerbations even when treated with steroid-based therapies. Because of unsatisfactory results obtained from currently available therapies for steroid-insensitive asthma, a better understanding of its pathogenesis and the development of new targeted molecular therapies are warranted. Recent studies indicated that levels of interleukin (IL)-17 are increased and both eosinophils and neutrophils infiltrate the airways of severe asthmatics. IL-17 is a proinflammatory cytokine mainly secreted from helper T (Th) 17 cells and is important for the induction of neutrophil recruitment and migration at sites of inflammation. This review focuses on the pathogenetic role of Th17 cells and their associated cytokines in steroid-insensitive asthma and discusses the prospects of novel therapeutic options targeting the Th17 signaling pathway.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Targeting the Th17 pathway. Helper T (Th) 17 cells are derived from naïve CD4+ T cells under the control of transforming growth factor (TGF)-β, interleukin (IL)-6, and IL-23 during stimulation by cognate antigen. These cytokines also stimulate Th 17 cells to produce IL-21, which affects Th17 cells themselves to activate a specific transcription factor, RORγt through autocrine regulation. Other proinflammatory cytokines, IL-1β and tumor necrosis factor (TNF)-α, may also promote Th17 development. RORγt regulates both Th17 cell differentiation and production of Th17-signature cytokines, IL-17A, IL-17F, IL-21, and IL-22. Among these cytokines, IL-17A and IL-17F play pivotal roles in the pathogenesis of asthma and share a common receptor subunit, IL-17 receptor A (IL-17RA), and IL-17 receptor C (IL-17RC). Several inhibitors of Th17 pathway are currently under clinical investigation.G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; IL-1R, IL-1 receptor; IL-6R, IL-6 receptor, Treg, regulatory T.

References

    1. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Journal of Respiratory and Critical Care Medicine. 2000;162(6):2341–2351. - PubMed
    1. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. Journal of Allergy and Clinical Immunology. 2001;107(6):963–970. - PubMed
    1. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. The Lancet. 2007;370(9596):1422–1431. - PubMed
    1. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. The New England Journal of Medicine. 2009;360(10):973–984. - PMC - PubMed
    1. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. American Journal of Respiratory and Critical Care Medicine. 2011;184(10):1125–1132. - PubMed